RxDoctor Payments Data

Lloyd Weddington, MD

Endocrinology, Diabetes & Metabolism · Marietta, GANPI 1043288418

Payments from drug & device makers

$6,880in general payments, 2019–2025

Across 395 payments — averaging $17.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$919
  • AbbVie$898
  • Amgen$688
  • Pfizer$467
  • Lilly USA, LLC$439
  • Sanofi-aventis U.S. LLC$315
  • plus $3K from 42 others

What the payments were for

  • Food & beverage$6,880100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,880 in reported general payments places this provider in the 65th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.

See all endocrinology, diabetes & metabolism providers in Georgia

Medicare billing

Part B allowed, 2024
$72,163
Medicare patients
276
Services billed
620

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin114$133,962
FarxigaDapagliflozin Propanediol40$55,072
MounjaroTirzepatide53$54,396
OzempicSemaglutide30$39,902
RybelsusSemaglutide30$34,757
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$29,989
JanuviaSitagliptin Phosphate18$27,334
TradjentaLinagliptin38$26,967
EliquisApixaban26$23,333
Tresiba Flextouch U-200Insulin Degludec13$20,612
BelsomraSuvorexant19$10,110
Isosorbide Dinitrate12$9,621
Repatha SureclickEvolocumab17$9,355
Tresiba Flextouch U-100Insulin Degludec15$8,664
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$7,635

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$72$160,929152 claims
Novo NordiskOzempic, Rybelsus, Novolog$919$79,25173 claims
AstraZenecaFarxiga$271$55,07240 claims
Lilly USA, LLCMounjaro$439$54,39653 claims
MerckJanuvia, Belsomra$141$37,44337 claims
GSKTrelegy Ellipta$280$29,98931 claims
PfizerEliquis$467$23,33326 claims
AbbVieSynthroid$898$3,60748 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$35$2,851324 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.

Other endocrinology, diabetes & metabolism in Marietta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →